Media
Hua Medicine To Present Comprehensive Data of its 24-week Monotherapy Trial Results at 2020 ADA Scientific Sessions
June 5, 2020, Shanghai, China
Hua Medicine (the"Company", Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announces that post-analysis data from dorzagliatin’s monotherapy clinical trial, a dual-acting glucokinase activator (GKA), will be presented in two presentations at the 80th American Diabetes Association (ADA) Annual Scientific Sessions to be held June 12-16, 2020.
This will be the first time for the Company to present the comprehensive results of the 24-week phase III monotherapy registration trial (HMM0301) of dorzagliatin at a major international diabetes conference. Hua Medicine has been presenting significant clinical achievements at the ADA Annual Scientific Sessions since 2014.
Company presentation details
Oral Presentation | |
Title： | A Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2dm Patients After 24 Weeks of Treatment in a Phase III Monotherapy Trial |
Abstract： | 2020‐A‐4397‐Diabetes |
Session： | Clinical Diabetes / Therapeutics Other Therapeutics Agents |
Time： | 8:45 a.m. - 9:00 a.m., Sunday, June 14, 2020 (US Central time) |
Authors： | Dalong Zhu, Yi Zhang, Li Chen |
In addition to the company presentation, clinical data from dorzagliatin will also be highlighted during a symposium session at the ADA.
Symposium | |
Title： | The Antidiabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes |
Session： | Chinese Diabetes Society Symposium — Novel Antidiabetic Approaches and Potential Targets |
Time： | 2: 45 p.m. - 3: 15 p.m., Monday, June 15th, 2020 (US Central time) |
Presenter： | Dalong Zhu, MD, PhD (President of the Chinese Diabetes Society, Director of Endocrinology at the Nanjing Drum Tower Hospital) |
About the Symposium
The ADA has arranged for a China Symposium during the Scientific Sessions to provide a venue for domestic and international experts to share data on from Chinese diabetes prevention, research, and treatment. The ADA China Symposium has become an important global stage for clinicians, researchers, and PIs.
The theme of this year’s China Symposium will be “Novel Antidiabetic Approaches and Potential Targets”. The session will be hosted by Dr. Dalong Zhu, Chairman of the Chinese Diabetes Society and Director of Endocrinology at the Nanjing Drum Tower Hospital. Dr. Zhu will present comprehensive clinical results, with clinical trials entirely conducted by teams in China, of a novel, first-in-class drug. In addition, as the lead PI of HMM0301, Dr. Zhu will unveil the study name for the first time.
About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 Diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 Diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Hua Medicine
Website: yi92.cn
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
